CVS - CVS Health Corporation

NYSE - NYSE Delayed price. Currency in USD
67.74
-2.35 (-3.35%)
At close: 4:02PM EDT

67.50 -0.24 (-0.35%)
Pre-market: 4:00AM EDT

Stock chart is not supported by your current browser
Previous close70.09
Open69.28
Bid66.92 x 3000
Ask67.64 x 1800
Day's range67.63 - 69.48
52-week range60.14 - 84.00
Volume7,482,783
Avg. volume8,684,375
Market cap68.868B
Beta0.85
PE ratio (TTM)10.39
EPS (TTM)6.52
Earnings date8 Aug 2018
Forward dividend & yield2.00 (2.85%)
Ex-dividend date2018-04-20
1y target est86.80
Trade prices are not sourced from all markets
  • Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
    Zacks4 days ago

    Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

    Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health

  • CVS Health Corporation (NYSE:CVS) Has Attractive Fundamentals, Here’s Why
    Simply Wall St.5 days ago

    CVS Health Corporation (NYSE:CVS) Has Attractive Fundamentals, Here’s Why

    CVS Health Corporation (NYSE:CVS) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In theRead More...

  • Barrons.com5 days ago

    Merger Arb Is Back in Vogue, and Bill Gross Is On It

    While the world focused on the shares of media companies after a federal judge approved AT&T's (T) proposed $85 billion acquisition of Time Warner (TWX), other industries also benefited from the prospects of mega-deals. As Barron's Varada Bhat wrote, the S&P 500's top-performing stocks on Wednesday were either already involved in merger activities, or those that might be. Pharmacy chain CVS Health (CVS) announced plans to acquire Aetna (AET) for $69 billion in December.

  • Should Value Investors Consider CVS Health (CVS) Stock Now?
    Zacks5 days ago

    Should Value Investors Consider CVS Health (CVS) Stock Now?

    CVS Health (CVS) appears to be a good choice for value investors right now, given its favorable P/E and P/S metrics.

  • MarketWatch6 days ago

    How the AT&T-Time Warner merger may boost shares of CVS and Express Scripts

    Court approval of the AT&T-Time Warner deal now makes it more likely that similar kinds of pending mergers will go through — and there’s a good investing angle in this. The green light in the deal appears to clear the way for CVS Health’s (CVS) planned acquisition of insurer Aetna (AET), and Cigna’s (CI) pending takeover of pharmacy-benefit manager (PBM) Express Scripts (ESRX).

  • How Big Is The AT&T-Time Warner Ruling? Even These Stocks Are Rallying
    Investor's Business Daily6 days ago

    How Big Is The AT&T-Time Warner Ruling? Even These Stocks Are Rallying

    A federal judge's ruling late Tuesday blessing the AT&T-Time Warner merger raised hopes that the CVS-Aetna and Cigna-Express Scripts deals will win antitrust approval.

  • Bloomberg6 days ago

    Health Deal Darlings Should Bask in AT&T Afterglow: Street Wrap

    Health insurers and pharmacy-benefit managers with a rash of billion-dollar deals on the line are likely breathing sighs of relief after AT&T Inc. won clearance to takeover Time Warner Inc. The long-awaited green-light bodes well for CVS Health Corp.’s proposed $68 billion acquisition of health insurer Aetna Inc. and Cigna Corp.’s $54 billion deal for Express Scripts Holding Co., according to analysts. Investors were concerned the tie-ups may be challenged by the U.S. Department of Justice as both mergers received “second request” notifications, Matt Borsch, an analyst at BMO Capital Markets, wrote in a note to clients.

  • Judge approves AT&T-Time Warner merger
    Yahoo Finance7 days ago

    Judge approves AT&T-Time Warner merger

    A judge ruled Tuesday that AT&T can complete its $85 billion acquisition of Time Warner.

  • Trump Health Chief Renews Call to End Key Drug-Pricing Tactic
    Bloomberg7 days ago

    Trump Health Chief Renews Call to End Key Drug-Pricing Tactic

    U.S. Health and Human Services Secretary Alex Azar told lawmakers that it may be time to eliminate the complex system of rebates that drug companies and pharmacy-benefit managers use to negotiate and set prices. Once drugmakers set a list price for a product, pharmacy-benefit managers like CVS Health Corp. and Express Scripts Holding Co. negotiate rebates. The PBMs have been criticized for keeping some of the rebates for themselves instead of passing them directly to consumers to lower their out-of-pocket costs.

  • CVS Health's PBM Selling Season Remains Solid, Retail Grows
    Zacks8 days ago

    CVS Health's PBM Selling Season Remains Solid, Retail Grows

    CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.

  • MarketWatch13 days ago

    CVS announces management team after CVS-Aetna deal

    CVS Health Corp. announced early Wednesday the management team that will serve once its acquisition of health insurer Aetna Inc. closes. Aetna Chief Financial Officer Shawn Guertin will serve as CVS Health's ...

  • Better Buy: CVS Health Corp vs. Kroger Co
    Motley Fool14 days ago

    Better Buy: CVS Health Corp vs. Kroger Co

    Both are under assault from the same behemoth, but one is in a better position for long-term sustainability.

  • Can CVS Health Corporation (NYSE:CVS) Continue To Outperform Its Industry?
    Simply Wall St.17 days ago

    Can CVS Health Corporation (NYSE:CVS) Continue To Outperform Its Industry?

    CVS Health Corporation (NYSE:CVS) delivered an ROE of 17.24% over the past 12 months, which is an impressive feat relative to its industry average of 13.74% during the same period.Read More...

  • CVS Health and Walgreens: Comparing Stock Upside
    Market Realist19 days ago

    CVS Health and Walgreens: Comparing Stock Upside

    CVS Health (CVS) and Walgreens Boots Alliance (WBA) shares have seen high levels of volatility in the past year. Walgreens, which is currently trading at $62.70 as of May 29, has seen its share price move between $61.56 to $83.89 in the last 12 months. CVS is trading at $64.80. CVS has a 52-week price range of $60.14–$84.

  • Analysts’ Take on CVS Health and Walgreens
    Market Realist19 days ago

    Analysts’ Take on CVS Health and Walgreens

    Walgreens Boots Alliance (WBA) and CVS Health (CVS) are both well-covered stocks. While Walgreens is tracked by 27 analysts, 25 analysts cover CVS.

  • What Are CVS Health and Walgreens’ Valuations?
    Market Realist19 days ago

    What Are CVS Health and Walgreens’ Valuations?

    Currently, Walgreens Boots Alliance (WBA) and CVS Health (CVS) are valued below their historical averages. Walgreens stock trades around 10.2x the next 12-month earnings. Walgreens stock touched the lower end of its 52-week forward PE range of 10.1x–15.8x. The stock’s three-year average PE ratio is even higher at 16x.

  • MarketWatch19 days ago

    Walgreens may be building the store of the future in Florida — but Wall Street is skeptical

    CVS Health Corp. is buying Aetna Inc., while Cigna Corp. is snapping up Express Scripts Holding Co. As health-care companies vertically integrate with high-priced deals across varied parts of the industry’s supply chain, Walgreens Boots Alliance Inc.(WBA) , its acquisition of rival Rite Aid’s (RAD)nearly 2,000 stores now complete, remains alone at the party. See: U.S. health care is changing in a big way.

  • CVS Health and Walgreens’ Stock Prices Fell
    Market Realist20 days ago

    CVS Health and Walgreens’ Stock Prices Fell

    Drugstore stocks have been under pressure in the past year due to fears of Amazon (AMZN) entering the pharma space, President Trump’s drug pricing policy change, and the ongoing consolidation wave in the industry.

  • CVS Health versus Walgreens: Comparing Pharmacy Giants
    Market Realist20 days ago

    CVS Health versus Walgreens: Comparing Pharmacy Giants

    Walgreens Boots Alliance (WBA) and CVS Health (CVS) are two well-known pharmacy giants. The two pharmacy giants control at least half of the market share in 70 of the top 100 metropolitan areas, according to research by Barclays. One of the pharmacies has a higher level of vertical integration, while the other pharmacy has a more significant international presence.

  • MarketWatch20 days ago

    These 5 undervalued dividend-paying stocks are worth a close look

    According to my firm’s performance tracking, it is one of the best-performing investment newsletters over the long term, beating the broad U.S. stock market by a large margin. Indeed, at the beginning of January, Wright’s valuation model found that, among the 244 stocks he monitored, there were twice as many overvalued as undervalued stocks.

  • MarketWatch24 days ago

    GE’s biggest mistake is doubling down on its habit of safe thinking

    A habit of safe thinking has been sinking General Electric for years. Since John Flannery took the helm last June, GE(GE) at every turn has shown a preference for incremental solutions, avoiding risk and averting its gaze from the massive changes its businesses face. In 2017, when activist investors finally lost patience with Jeffrey Immelt, they replaced him with Flannery, the classic company man.

  • MarketWatch28 days ago

    CVS-Aetna merger is not about the minute clinic, Aetna CEO says

    CVS Health’s recent acquisition of Aetna has sparked talk of a pharmacy of the future, in which CVS’s walk-in “minute clinics” offer more services, and in a more accessible way than traditional health care. Bertolini, who has previously compared this goal to Apple’s (AAPL) Genius Bar, said CVS stores and services could become a “tent without walls,” by say, encouraging an individual with Type 1 diabetes named Sally to exercise a certain amount and keep her hemoglobin levels below a certain point.

  • Top Gainers in the Consumer Sector Last Week
    Market Realistlast month

    Top Gainers in the Consumer Sector Last Week

    TripAdvisor (TRIP) reported its first-quarter results on May 10. Its revenue grew 1.6% to $378 million and surpassed the consensus estimate by 4.6%. It reported a drastic increase in earnings to $0.30 per share compared to EPS (earnings per share) of $0.24 in the first quarter of 2017. Its EPS also surpassed the consensus estimate of $0.16 per share. The stock rose 24.2% last week.

  • 3 Top Stocks With High Dividend Yields
    Motley Foollast month

    3 Top Stocks With High Dividend Yields

    These dividend stocks could give your income portfolio a big boost.

  • Barrons.comlast month

    CVS, Aetna Deal Has a 70% Chance of Closing. Here's What Happens If It Doesn't.

    Managed-care organizations showed healthy upside in the first quarter, but the biggest story in MCO-land remains, of course, the upcoming CVS Health (CVS) acquisition of Aetna (AET). Credit Suisse analyst A.J. Rice in a Monday research report lowered his Aetna target to $194 from $208 but remains Neutral on the stock. "We use a 70% probability that the AET-CVS deal is approved ($197 deal price based on current CVS price).